Edwards' $45 Mil. Sale Of CRI Marks End Of Post-Baxter Restructuring
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences has completed the divestment phase of its ongoing reorganization strategy with the sale of its $120 mil. perfusion services business, Cardiovascular Resources, Inc. (CRI), to Fresenius Medical Care for $45 mil.